Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 928

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 928
---
 annual maintenance fees during each of the years ended December 31, 2023 and 2022. The Company also incurred $125,000 in milestone payments in each of the years ended December 31, 2023 and 2022, respectively, in relation to the initiation of two Phase 2 clinical trials. To date, no royalty fees have been incurred. All related license costs are expensed as incurred within research and development on the statements of operations and comprehensive loss.

#### 15. Retirement Savings Plan
The Company maintains a 401(k) Plan which is available to all employees. Under the terms of the 401(k) Plan, participants may elect to contribute up to 80% of their compensation or the statutory prescribed limits. The Company does not make any matching contributions to deferrals made by participants.

#### 16. Related-party Transactions
During the years ended December 31, 2023 and 2022, the Company did not have any transactions with related parties. The Company evaluates transactions with counterparties who may be considered related parties, including owners, members of management or affiliates and then discloses the nature and amounts of those transaction in the notes to its financial statements.

#### 17. Subsequent Events
In January of 2024, the Company terminated its Phase 1/b clinical trial for metastatic breast cancer. In connection with the termination, the Company will be responsible for certain costs to close the clinical trial. The Company will recognize these remaining costs to close the clinical trial during 2024 under the Company’s expense policy related to clinical trials.

Management has evaluated all other subsequent events through October 4, 2024, which was the date the financial statements were available to be issued and has determined that there are no subsequent events to be reported.

<div align='center'>F-114</div>

TABLE OF CONTENTS

Tvardi Therapeutics, Inc. CONDENSED Balance Sheets
(Amounts in thousands, except share and per share amounts)
(Unaudited)

| ​                                                                                                                                                                                                                                                                                                                                        
 Assets                                                                                                                                                                                                                                                                                                                                   
 Current assets:                                                                                                                                                                                                                                                                                                                          | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | As ofSeptember 30,2024 
 ​                      
 ​                      | ​ 
 ​ |       ​ 
       ​ | ​ 
 ​ | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | As ofDecember 31,2023 
 ​                     
 ​                     | ​ 
 ​ |       ​ 
       ​ | ​ 
 ​ | ​ 
 ​ 
 ​